THERAPY DOSSIER · th-217e55911c6f

Bis(aspirinato)zinc(II) [Zn(ASA)2]

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26497333 ↗2015Reported benefit

Administration of zinc complex of acetylsalicylic acid after the onset of myocardial injury protects the heart by upregulation of antioxidant enzymes.

RatChemical/toxinSprague-DawleyMaleAdministered after the isoproterenol injection, that is after the onset of acut…

Model: Isoproterenol-induced acute myocardial injury/ischaemia

Zn(ASA)2 given after isoproterenol prevented inflammatory infiltration, DNA strand breakage, the rise in 11-dehydro-thromboxane B2 and the electrocardiographic changes, significantly improved load-independent left ventricular contractility, and increased myocardial superoxide dismutase-1 and glutat…

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…